2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. As of May 13, 2025, 2seventy bio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Metrics to compare | TSVT | Peers Peers - average of corresponding metrics from companies closely matching TSVT: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTSVTPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 37.4% | |
Fair Value Upside | Unlock | 0.0% | 4.5% | Unlock |